3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
8
Neuroblastoma
4
Retinoblastoma
3
Fallopian Tube Neoplasms
3
Sarcoma, Ewing
2
Lung Neoplasms
2
Ganglioneuroblastoma
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Recurrence
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Glioma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
selinexor
1
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Drug Therapy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
Topotecan
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled